First and Only Once-Weekly Type 2 Diabetes Medication Delivers Powerful Glycemic Control in a Single Dose INDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., June 21, 2011 /PRNewswire/ -- Eli Lilly and ...

Amylin said weekly diabetes shot Bydureon, launched in February, is gaining market share among influential physicians but expects the med’s profit margins to be low for some time. Bydureon brought in ...

If you have type 2 diabetes, your doctor may suggest Bydureon BCise (exenatide extended-release) as a treatment option. Along with other factors, you may have questions about possible side effects of ...

PHILADELPHIA-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced clinical study results which showed that a significantly greater proportion of patients ...

Data from Nearly 1,100 Patients in DURATION-1, -2 and -3 Trials Showed BYDUREON was Well-Tolerated ORLANDO, Fla.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company ...

PHILADELPHIA-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON™ ...

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

Forbes contributors publish independent expert analyses and insights. I cover the pharmaceutical industry. As pundits continue to ponder the unanswered questions surrounding Amylin Pharmaceuticals and ...

Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study. Bydureon ...

SAN DIEGO, June 24 (Reuters) - Analysis of an earlier trial found a "clinically insignificant" link between changes in heart rhythms and use of Bydureon, a long-acting diabetes drug being developed by ...

BYDUREON works with the body to help make its own insulin when needed, providing continuous glycemic control with just one dose per week. Using Alkermes’ proprietary technology for long-acting ...